RecruitingNCT04124029
Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)
Contributions of Mild Traumatic Brain Injury to Neurodegeneration Due to Chronic Traumatic Encephalopathy and Alzheimers Disease
Sponsor
VA Office of Research and Development
Enrollment
800 participants
Start Date
Jul 1, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
This is a research study that aims to examine whether Veterans with mild Traumatic Brain Injuries are at risk for dementia by studying their memory, brain wave activity, brain structure and proteins that can be elevated after brain injury and in dementia.
Eligibility
Min Age: 30 YearsMax Age: 90 Years
Inclusion Criteria39
- All Subjects:
- Intact color vision
- Visual acuity of 20/30 (or better)
- Patients must pass effort measures on the TOMM
- Patients must have intact decision-making capacity
- Patients must have no contraindications to lumbar puncture including:
- Being on a blood thinner
- Aspirin or Plavix
- Have no space occupying lesion on magnetic resonance imaging (MRI)
- An International Normalized Ratio (INR) value \< 1.4 and platelet count \>50,000
- No epidural infection or overlying cellulitis over the lumbar spine
- PTSD will be accounted for as a potential confounder and its presence will be included as a covariate in all analyses
- Mild TBI Subjects:
- Subjects will be recruited who have a physician diagnosis of 1 or more mTBI episodes without concomitant moderate or severe TBI diagnosis
- Mild TBI: Loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, and/or altered mental status greater than 24 hours
- Moderate TBI Subjects:
- Subjects will be recruited who have a physician diagnosis of 1 or more moderate TBI episodes
- Moderate TBI: loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, and altered mental status greater than 24 hours
- MCI Subjects:
- Subjects will be recruited that meet diagnostic criteria for MCI (without a history of TBI) based on the judgement of a behavioral neurologist following the 2011 MCI criteria
- Specifically, subjects will test in the impaired range on one or more cognitive domains on neuropsychological testing and will not have impairments in function, i.e. will not meet diagnostic criteria for dementia
- Subjects with MCI may or may not meet diagnostic criteria for MCI due to AD
- MCI subjects will be matched for their MoCA score with older TBI subjects
- Healthy Controls:
- Cognitively normal control subjects, age-, education- and sex-matched with mild TBI subjects, but lacking and TBI history
- All subjects must be within 1 standard deviation of normal on all neuropsychologic testing in order to be enrolled
- The investigators will recruit all subjects without regard to gender, race, ethnicity, socioeconomic status, or other factors to allow results of this research to yield the greatest generalizability
- Impaired decision-making ability
- Patients will be excluded if there are contraindications to MRI including:
- Implants
- Shrapnel
- Aneurysm clips
- Pacemaker
- Pregnancy
- Non-TBI subjects must not have had an TBI
- No contraindication to lumbar puncture or blood draw including:
- Being on a blood thinner
- Aspirin or Plavix
- No space occupying lesion on MRI that makes lumbar puncture contraindicated
Exclusion Criteria9
- All Subjects:
- If the primary language is not English
- Are unable to understand the informed consent process
- Have a clinically significant problem with any of the following conditions:
- A history of TBI within 1 year of study
- Suicidal or homicidal ideation requiring intervention
- Schizophrenia
- Bipolar disorder
- Active alcohol or drug abuse
Interventions
DEVICENo Intervention is used for this study but all subjects will be asked to complete EEG testing and an MRI scan.
No intervention will be used.
PROCEDURENo intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.
No intervention will be used.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04124029
Related Trials
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT071696301 location
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
NCT064675391 location
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
NCT041233141 location
Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD
NCT058812391 location
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
NCT065481911 location